High frequency of Specific Polysaccharide ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
Titre :
High frequency of Specific Polysaccharide Antibody Deficiency (SPAD) in adults with unexplained, recurrent and/or severe infections with encapsulated bacteria.
Auteur(s) :
Stabler, Sarah [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Lamblin, Catherine [Auteur]
Ramsay Générale de Santé - Hôpital Privé La Louvière
Gaillard, Sacha [Auteur]
Juste, Nicolas [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Mihailescu, Mirela [Auteur]
Viget, Nathalie [Auteur]
Sy Ndiaye, Thierno [Auteur]
Dzeing Ella, Arnaud [Auteur]
Weyrich, Pierre [Auteur]
Groupe Hospitalier de l'Institut Catholique de Lille [GHICL]
Prevotat, Anne [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Chenivesse, Cecile [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Le Rouzic, Olivier [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Mortuaire, Geoffrey [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Vuotto, Fanny [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Faure, Karine [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Leurs, Amelie [Auteur]
Wallet, Frederic [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Loiez, Caroline [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Institut de Microbiologie [CHRU Lille]
Titecat, Marie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Le Guern, Rémi [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Sanges, Sebastien [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Etienne, Nicolas [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Launay, David [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lopez, Benjamin [Auteur]
Institut d'Immunologie [CHRU Lille]
Bahuaud, Mathilde [Auteur]
Institut Cochin [IC UM3 (UMR 8104 / U1016)]
Batteux, Frédéric [Auteur]
Institut Cochin [IC UM3 (UMR 8104 / U1016)]
Dubucquoi, Sylvain [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Gesquière-Lasselin, Cyrielle [Auteur]
Institut d'Immunologie [CHRU Lille]
Labalette, Myriam [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lefevre, Guillaume [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Lamblin, Catherine [Auteur]
Ramsay Générale de Santé - Hôpital Privé La Louvière
Gaillard, Sacha [Auteur]
Juste, Nicolas [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Mihailescu, Mirela [Auteur]
Viget, Nathalie [Auteur]
Sy Ndiaye, Thierno [Auteur]
Dzeing Ella, Arnaud [Auteur]
Weyrich, Pierre [Auteur]
Groupe Hospitalier de l'Institut Catholique de Lille [GHICL]
Prevotat, Anne [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Chenivesse, Cecile [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Le Rouzic, Olivier [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Mortuaire, Geoffrey [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Vuotto, Fanny [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Faure, Karine [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Leurs, Amelie [Auteur]
Wallet, Frederic [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Loiez, Caroline [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Institut de Microbiologie [CHRU Lille]
Titecat, Marie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Le Guern, Rémi [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Sanges, Sebastien [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Etienne, Nicolas [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Launay, David [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lopez, Benjamin [Auteur]
Institut d'Immunologie [CHRU Lille]
Bahuaud, Mathilde [Auteur]
Institut Cochin [IC UM3 (UMR 8104 / U1016)]
Batteux, Frédéric [Auteur]
Institut Cochin [IC UM3 (UMR 8104 / U1016)]
Dubucquoi, Sylvain [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Gesquière-Lasselin, Cyrielle [Auteur]
Institut d'Immunologie [CHRU Lille]
Labalette, Myriam [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lefevre, Guillaume [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Titre de la revue :
Clinical Infectious Diseases
Éditeur :
Oxford University Press (OUP)
Date de publication :
2022-10-27
ISSN :
1058-4838
Mot(s)-clé(s) en anglais :
Streptococcus pneumoniae
vaccine response
primary immunodeficiency
specific anti-polysaccharide deficiency (SPAD)
vaccine response
primary immunodeficiency
specific anti-polysaccharide deficiency (SPAD)
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
BackgroundPrimary immunodeficiencies (PIDs) in adults are mainly revealed by recurrent and/or severe bacterial infections. The objective of this study was to evaluate a systematic research strategy of PIDs in adults with ...
Lire la suite >BackgroundPrimary immunodeficiencies (PIDs) in adults are mainly revealed by recurrent and/or severe bacterial infections. The objective of this study was to evaluate a systematic research strategy of PIDs in adults with unexplained bacterial infections, with a special focus on specific polysaccharide antibody deficiency (SPAD).MethodsIn this prospective multicenter study, inclusion criteria were recurrent benign upper and lower respiratory tract infections (RTIs) for at least two years (group 1), at least one upper or lower RTI requiring hospitalization (group 2), and/or at least one invasive infection documented with encapsulated bacteria (group 3). Main exclusion criteria were all local and general conditions that could explain infections. If no PID diagnosis was made, response to polysaccharide antigens was assessed using a pneumococcal polysaccharide vaccine.ResultsFrom March 2015 to March 2020, 118 patients were included (37 males, median age of 41 years): 73, 17, and 28 in groups 1, 2, and 3, respectively. Forty-seven PIDs were diagnosed, giving an estimated frequency of 39.8% (95% confidence interval [CI] [30.4, 48.8]). SPAD was the most frequent diagnosis by far (n = 37/47, 78.7%), and was made in 23, 5, and 9 patients from groups 1 to 3, respectively. All SPAD patients received conjugate vaccines and, according to their infectious history, were on surveillance or treated with preventive antibiotics (n = 6) and/or with immunoglobulins replacement therapy (n = 10), the latter being dramatically efficient in all cases.ConclusionsConsidering its high prevalence among adults with unexplained recurrent and/or severe bacterial infections, SPAD should be screened in those patients.Clinical Trials RegistrationNCT02972281.Lire moins >
Lire la suite >BackgroundPrimary immunodeficiencies (PIDs) in adults are mainly revealed by recurrent and/or severe bacterial infections. The objective of this study was to evaluate a systematic research strategy of PIDs in adults with unexplained bacterial infections, with a special focus on specific polysaccharide antibody deficiency (SPAD).MethodsIn this prospective multicenter study, inclusion criteria were recurrent benign upper and lower respiratory tract infections (RTIs) for at least two years (group 1), at least one upper or lower RTI requiring hospitalization (group 2), and/or at least one invasive infection documented with encapsulated bacteria (group 3). Main exclusion criteria were all local and general conditions that could explain infections. If no PID diagnosis was made, response to polysaccharide antigens was assessed using a pneumococcal polysaccharide vaccine.ResultsFrom March 2015 to March 2020, 118 patients were included (37 males, median age of 41 years): 73, 17, and 28 in groups 1, 2, and 3, respectively. Forty-seven PIDs were diagnosed, giving an estimated frequency of 39.8% (95% confidence interval [CI] [30.4, 48.8]). SPAD was the most frequent diagnosis by far (n = 37/47, 78.7%), and was made in 23, 5, and 9 patients from groups 1 to 3, respectively. All SPAD patients received conjugate vaccines and, according to their infectious history, were on surveillance or treated with preventive antibiotics (n = 6) and/or with immunoglobulins replacement therapy (n = 10), the latter being dramatically efficient in all cases.ConclusionsConsidering its high prevalence among adults with unexplained recurrent and/or severe bacterial infections, SPAD should be screened in those patients.Clinical Trials RegistrationNCT02972281.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Source :